Eficacia, seguridad y tolerabilidad del policosanol en pacientes con hipercolesterolemia tipo II: Estudio abierto

Prensa Medica Argentina

Volumn 83, Issue 7, 1996, Pages 665-672

  Campilongo, R ^a   Sandin, D ^a   Feldman, R ^a   Barrios, O ^a   Abbonizio, A ^a   Masnu, R ^a   Venturini, A ^a   Esteguy, A ^a   Herrera, M ^a   Ciaburri, L ^a   Rosenthal, P ^a   Valsmaris, M ^a   Martino, O ^a   Antonioli, A ^a   Lago, P ^a   Wingiel, M ^a   Vazzano, A ^a   Lauro Rodriguez, C ^a   Mele, O ^a   Lozano, D ^a   Montero, N ^a   Pellegrini, H ^a   Motto, M ^a   Bluntritt, M ^a   Picco, S ^a   Cerruti, J ^a   Arena, A ^a   Sosa, A ^a   Hernandorena, T ^a   Naveira, A ^a   Lati, A ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001452846     PISSN: 0032745X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ALEMAN, C. L.; MAS, R.; HERNANDEZ C.; RODEIRO, I.; CEREJIDO, E.; NOA, M.; CAPOTE, A.; MENENDEZ, R.; AMOR A. M.; GONZALEZ, R. M.; SOTOLONGO, V. and JIMENEZ S.: A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol. Lett, 70: 77-87, 1994a.
2. ALEMAN, C. L.; MAS, R.; NOA, M.; RODEIRO, I.; HERNANDEZ, C. and CAPOTE, A.;: Carcinogenicity of policosanol in Sprague Dawleyrats: A 24 months study. Teratogenesis, Carcinogenesis and Mutagenesis, 14: 239-249, 1994b.
3. ALEMAN, C. L.; NOA, M.; CEREJIDO E.; MAS R.; RODEIRO, I.; HERNANDEZ, C. and BRIÑIS, F.: Carcinogenicity of policosanol in mice: A 18 months study. Food and Chem. Toxicol., 33: 573-578, 1995.
4. ANEIROS, E.; MAS, R.; CALDERON, B.; ILLNAIT, J.; FERNANDEZ, L.; CASTAÑO, G. and FERNANDEZ, J. C.: Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemy. Curr. Ther. Res., 56: 176-182, 1995.
5. ARRUZAZABALA, M. L.; CARBAJAL, D.; MAS, R.; MOLINA, V.; VALDES, S. and LAGUNA A.: Cholesterol-lowering effects of policosanol in rabbits. Biol. Res., 27: 205-208, 1994.
6. BOCCUZZI, S. J.; KEEGAN, M. E.; HIRSCH, L. J.; SHAPIRO, D. R.; PLITKIN, D. J. and MITCHEL, Y. B.: Long Term Experience with simvastatin. Drug Invest. 5: 135-140, 1993.
7. CANNETTI, M.; MOREIRA, M.; ILLNAIT, J.; MAS, R.; FERNANDEZ, L.; CASTAÑO, G and FERNANDEZ J. C.: One year study on the effect of polisosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Ad. Ther., 12:245-254.
8. CASTAÑO, G.; ZARDOYA, R.; ILLNAIT, J.; MAS, R.; FERNANDEZ, L.; SURRIBAS, E.; NODARSE, M. y FERNANDEZ, J. C.: Efectos del tratamiento con Ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM 5:21-28, 1991.
9. CASTAÑO, G.; MAS, R.; NODARSE, M.; ILLNAIT, J.; FERNANDEZ, L. and FERNANDEZ, J. C.: One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the tratment of type II huypercholesterolemia. Curr. Ther. Res., 56: 296-304, 1995.
10. CASTAÑO, G.; TULA, L.; CANETTI, M.; MORERA, M.; MAS, R.; ILLNAIT, J.; FERNANDEZ L. and FERNANDEZ, J.C.: Effect of policosanol (10 mg/day) in hyupertensive patients with primary hypercholesterolemia. Curr. Ther. Res., 1996, (in press).
11. FRICK, M. H.; ELO, D.; HAAPA, D. et al.: Helsinki Heart Study; primary-intervention trial with gemfibrozil in middle-aged men with dislipidemia. N. Engl. J. Med. 317: 1237-1245, 1987.
12. FRIEDEWALD, W. T.; LEVY, R. I. and FRIEDERICKSON, S. D.: Estimation on the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifugue. Clin. Chem. 18:499-502, 1972.
13. HEEL, R. C. et al.: Colestipol. A review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs, 19: 161-180, 1980.
14. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 251: 351-364, 1984a.
15. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering, JAMA, 251: 365-374, 1984b.
16. MENENDEZ, R.; FERNANDEZ, I.; DEL RIO, A.; GONZALEZ, R. M.; FRAGA, V.; AMOR, A. M.; JIMENEZ S. and MAS, R.: Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol. Res., 27: 199-203, 1994.
17. MESA, A. R.; MAS, R.; NOA, M.; HERNANDEZ, C.; RODEIRO, I.; GAMEZ, R.; GARCIA, M.; CAPOTE A. and ALEMAN, C. L. Toxicity of policosanol in Beagle dogs: one year study. Toxicol. Lett., 73:81-90, 1994.
18. MONK, J. P. and TODD, P. A. BEZAFIBRATE: A Review of tis Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Hyperlipidaemia. Drugs. 33: 539-576, (1987).
19. NEATON, J. D.; WENTWORTH D for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smokin and death from coronary hear disease. Overall findings and differences by age for 316, 099 white men. Arch Intern. Med., 64: 152-156, 1992.
20. O'CONNOR, O.; FEELY, J. and SHEPHERD, J.: Lipid lowering drugs. Br. Med. J., 300: 667-672, 1990.
21. PONS, P.; RODRIGUEZ, M.; ROBAINA, C.; ILLNAIT, J.; MAS, R.; FERNANDEZ, L. and FERNANDEZ, J. C. Effects of succesive dose increases of policosanol on the lipid profile of patients with type II hypercholestrolemia and tolerability to treatment. J. Clin. Pharmacol. Res., XIV, No 1: 27-33, 1994a.
22. PONS, P.; RODRIGUEZ, M.; MAS, R.; ILLNAIT, J.; FERNANDEZ, L.; ROBAINA C. and FERNANDEZ, J. C.: One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr. Ther. Res., 55: 1084-1092, 1994b.
23. RODRIGUEZ, C.; MESA, R.; MAS, R.; AMOR A. M. y CASTAÑO, G.: Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch. Venezol. Farmacol. Terap., 11: 74-79, 1992.
24. Scandinavian Simbastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simbastatin Survival Study (4S). The Lancet, 344: 1383-1389, 1994.
25. SOLTERO, I.; FUENMAYOR, I. y COLMENARES, J.: Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch. venezol. Farmacol. Terap., 12: 71-76, 1993.
26. STEINER, A.; WEISSER, B. and VETTER, W.: A comparative study of the adverse effects of treatments for huyperlipidaemia. Drug Safety, 6: 118-130, 1991.
27. Study Group, European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur. Heart. J., 8: 77-88, 1987.
28. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA, 269: 3015-3023, 1993.
29. The Paravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am. J. Cardiol, 72: 1031-1033, 1993.
30. TORRES, O.; AGRAMONTE, A. J.; ILLNAIT, J.; MAS, R.; FERNANDEZ, L. and FERNANDEZ, J. C.: Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care, 18: 393-397, (1995).